Developer docs
API playgroundTry for free, no card

Search company profiles

LPIXEL

Full company profile

uuid0002dqz

Namestring
LPIXEL
Legal namestring
エルピクセル株式会社
Websiteurl
lpixel.net
Company typeenum
Private
Founded yearint
2014
Descriptiontext

LPIXEL Inc. (エルピクセル株式会社) is a University of Tokyo spin-off founded in March 2014 that develops AI-powered medical image analysis software for clinical diagnostics and pharmaceutical research. Its flagship product family, EIRL, is a suite of regulated Software as a Medical Device (SaMD) products that deploy deep-learning computer vision across brain MRI (aneurysm detection), chest X-ray (lung nodule detection), chest CT, colonoscopy (polyp detection with differential diagnosis), and laparoscopic surgery support. The company also operates IMACEL, an AI platform for drug discovery image analysis, and ImaChek, an automated image-manipulation detection service for scientific publication integrity. The core technology stack comprises proprietary deep-learning models trained on the company's accumulated imaging dataset of more than 12 million cases, with multiple PMDA-approved SaMD products and EN ISO 13485:2016 medical-device quality certification.

The company generates revenue through enterprise SaaS subscriptions, per-case usage pricing, and one-time licenses for certified medical devices, sold through a direct enterprise sales motion targeting Japanese hospitals, complemented by channel partnerships with PACS providers (Jamac System) and medical equipment distributors (Ryukyu Kowa). Customers include more than 1,000 medical institutions across all 47 Japanese prefectures, plus major pharmaceutical companies (Takeda, Astellas, Daiichi Sankyo, Taiho) for drug discovery image analysis. Distribution is increasingly bundled into OEM platforms of Canon Medical Systems (Abierto), Siemens Healthineers (teamplay), NOBORI, M3, and Alamy Join AI Connect, giving LPIXEL reach into installed bases of imaging hardware and PACS networks. Strategic capital partners include Canon Medical Systems, Fujifilm, Olympus, Cyberdyne, and JAFCO, with cumulative disclosed funding of approximately $43 million across Series A (2016), a strategic round (2018), and follow-on capital in 2020 and 2025.

Short descriptiontext

LPIXEL is a Japan-based medical AI company that develops regulated deep-learning image-analysis software (EIRL suite) for radiology, endoscopy, and surgical guidance, serving hospitals and pharmaceutical research customers across Japan and expanding into ASEAN and MENAT markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, diagnostic support software, radiology workflow, drug discovery AI, medical device software
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Software Publishers5132
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
Product category
Medical Imaging AI / Diagnostic Imaging Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS Subscription
TypeSubscription Recurring
Description

Cloud-based subscription model providing AI analysis services to medical institutions on a recurring basis

2Per-Case Pricing
TypeUsage Based
Description

Usage-based pricing where healthcare facilities pay per analysis performed

3Medical Device Sales
TypeOne Time License
Description

Sale of certified medical device software products (EIRL series)

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise institutional licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed

GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1EIRL (エイル)
Description

AI medical image diagnostic support technology for clinical use, including brain MRI, chest X-ray, and colonoscopy analysis.

lpixel.net
+2 more records
Core offering1 text field

LPIXEL develops and sells AI-powered medical image diagnostic support software (EIRL series) covering brain MRI, chest X-ray, chest CT, and colonoscopy analysis for hospitals and clinics, as well as the IMACEL cloud platform for AI-assisted drug discovery research and ImaChek for image integrity checking in scientific publications. Products are deployed as regulated Software as a Medical Device (SaMD) with PMDA approval, EN ISO 13485:2016 certification, and integrations with PACS, medical imaging equipment, and cloud platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 1,000 medical institutions across Japan using LPIXEL solutions
+2 more records
Product and service11 records
1EIRL Brain Aneurysm
CategoryDiagnostic Imaging AI
Description

AI-powered Software as a Medical Device that analyzes brain MRI images to detect cerebral aneurysms, designed for radiology departments in hospitals and imaging centers.

2EIRL BRAIN
CategoryDiagnostic Imaging AI
Description

AI brain MRI analysis product family for detecting and characterizing brain lesions, used by radiologists in clinical practice.

3EIRL Chest Nodule
CategoryDiagnostic Imaging AI
Description

AI software that detects lung nodule candidate areas from chest X-ray images for radiologist review.

4EIRL Chest Screening
CategoryDiagnostic Imaging AI
Description

Multifunctional chest X-ray AI product integrating lung nodule detection and quantitative chest measurements for screening workflows.

5EIRL Chest CT
CategoryDiagnostic Imaging AI
Description

AI software for detecting lung nodule candidate areas from chest CT images, expanding the EIRL chest product line beyond X-ray.

6EIRL Colon Polyp
CategoryDiagnostic Imaging AI
Description

AI-assisted colonoscopy analysis software that detects colon polyp candidates in real time and assists in colonoscopy procedures, compatible with Olympus and Fujifilm endoscope systems.

7EIRL Viewer
CategoryDiagnostic Imaging AI
Description

Medical imaging display and analysis platform for viewing and interpreting EIRL AI analysis results within clinical workflows.

8EIRL Surgery LC
CategorySurgical AI / Diagnostic Imaging AI
Description

AI-powered landmarking and guidance system for laparoscopic cholecystectomy, supporting minimally invasive surgical procedures.

9IMACEL
CategoryDrug Discovery AI / Life Science Software
Description

AI-based image analysis cloud platform for drug discovery and life science research, supporting study design, seeds findings, and evaluation of diseases through phenotypic screening and cell morphology analysis.

10IMACEL Platform
CategoryDrug Discovery AI / Life Science Software
Description

Cloud-based image analysis AI platform for drug discovery and academic research, providing efficiency, quality, and safety improvements across the drug development pipeline.

11ImaChek
CategoryResearch Integrity Software
Description

Automated image manipulation and duplication checking system that extracts images from PDF scientific papers and compares them against databases to detect image fraud and honest errors, supporting research integrity.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Jameel Health
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Strategic collaboration to expand AI medical imaging solutions to MENAT (Middle East, North Africa, Turkey) and Global South markets. Joint go-to-market efforts for healthcare AI deployment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Comprehensive partnership for AI image analysis in pharmaceutical research and drug development. Collaboration focused on applying AI image analysis to support Daiichi Sankyo's drug development pipeline.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Strategic partnership for AI-based landmarking and guidance system for laparoscopic cholecystectomy. Joint development of AI-powered surgical guidance technology for minimally invasive procedures.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Business alliance for potential synergies in medical technology and AI solutions. Collaborative exploration of healthcare AI applications.

Strategic tierNotableTypeTechnology or Integration
Description

Technology partnership for system integration and deployment of AI medical imaging solutions. Collaboration on healthcare IT infrastructure.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Partnership for mammography AI development and deployment. Collaboration on breast cancer screening AI solutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AI image analysis partnership for pharmaceutical research and clinical trials. Application of AI to support Takeda's drug development activities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for AI-powered image analysis in pharmaceutical research. Collaboration on applying AI to Astellas research programs.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

AI image analysis partnership for research applications. Support for Taiho's pharmaceutical research initiatives.

10VNPT-IT
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint proof-of-concept initiative in Vietnam for AI medical imaging deployment. Market exploration and pilot programs in Southeast Asia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint proof-of-concept in Vietnam. Collaborative pilot programs for AI medical imaging solutions.

12Tokyo University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for clinical validation and research collaboration on AI medical imaging technologies. Joint research and product development.

13National Cancer Center Japan
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership for cancer screening AI development and clinical validation. Collaborative development of cancer detection AI solutions.

14Jamac System
Strategic tierNotableTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership through PACS provider for market access. Integration and resale of LPIXEL AI solutions through medical imaging systems.

15Ryukyu Kowa
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for medical imaging products in regional Japan markets.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
1AI Medical Service
TypeDirect peer
Description

Tokyo-based medical AI company developing endoscopy/colonoscopy diagnostic support AI. Directly comparable to LPIXEL as a Japanese SaMD-focused medical imaging AI company with PMDA approvals, hospital channel sales, and overlapping colonoscopy product (EIRL Colon Polyp vs. AI Medical Service's endoscopic AI).

TypeDirect peer
Description

Belgium-based AI company with FDA-cleared and CE-marked brain MRI quantification tools (icoBrain) for multiple sclerosis, dementia, and traumatic brain injury. Closely comparable to LPIXEL's EIRL Brain Aneurysm in modality (brain MRI), regulatory pathway (SaMD), and clinical use case (neuroimaging decision support).

TypeBroad incumbent
Description

Israel-based medical imaging AI platform with broad multi-modality FDA-cleared products covering CT, X-ray, and MRI triage and workflow across numerous clinical indications. Competes with LPIXEL's EIRL suite in modality breadth and hospital enterprise sales motion, but at much larger scale (Series D+ funding, global footprint).

TypeBroad incumbent
Description

US-based AI company specializing in clinical workflow AI for stroke and other time-sensitive conditions, with FDA-cleared products integrated into hospital imaging platforms. Comparable to LPIXEL as a regulated medical imaging AI company selling into enterprise health systems via PACS/workflow integrations, though narrower in modality focus.

TypeBroad incumbent
Description

US-based medical imaging AI company with FDA-cleared products for stroke, aneurysm, and PE imaging analysis on CT/MRI. Directly comparable in regulatory pathway (SaMD clearances), modality overlap (brain aneurysm detection), and enterprise radiology channel to LPIXEL's EIRL Brain Aneurysm.

TypeDirect peer
Description

US-based AI SaMD company analyzing coronary CT angiography for non-invasive FFR assessment. Comparable as a regulated imaging-AI SaMD with similar enterprise hospital sales motion, large PMA/FDA-cleared product portfolio, and reliance on CT scanner-installed-base partnerships.

TypeEmerging player
Description

US-based AI company with FDA-cleared mammography AI for breast cancer detection (cmTriage, cmAssist). Adjacent comparable to LPIXEL via the EIRL AI Partner Program's FathomX mammography integration, sharing the same regulated mammography SaMD category and women's imaging customer base.

TypeDirect peer
Description

US-based cloud-native medical imaging AI platform with FDA-cleared products for cardiac MRI, lung CT, and oncology workflows. Comparable to LPIXEL as a multi-modality cloud imaging AI platform selling to radiology departments through enterprise and PACS channels.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LPIXEL

Medical Imaging AI / Diagnostic Imaging Softwarelpixel.net

LPIXEL is a Japan-based medical AI company that develops regulated deep-learning image-analysis software (EIRL suite) for radiology, endoscopy, and surgical guidance, serving hospitals and pharmaceutical research customers across Japan and expanding into ASEAN and MENAT markets.

What LPIXEL does

LPIXEL Inc. (エルピクセル株式会社) is a University of Tokyo spin-off founded in March 2014 that develops AI-powered medical image analysis software for clinical diagnostics and pharmaceutical research. Its flagship product family, EIRL, is a suite of regulated Software as a Medical Device (SaMD) products that deploy deep-learning computer vision across brain MRI (aneurysm detection), chest X-ray (lung nodule detection), chest CT, colonoscopy (polyp detection with differential diagnosis), and laparoscopic surgery support. The company also operates IMACEL, an AI platform for drug discovery image analysis, and ImaChek, an automated image-manipulation detection service for scientific publication integrity. The core technology stack comprises proprietary deep-learning models trained on the company's accumulated imaging dataset of more than 12 million cases, with multiple PMDA-approved SaMD products and EN ISO 13485:2016 medical-device quality certification.

The company generates revenue through enterprise SaaS subscriptions, per-case usage pricing, and one-time licenses for certified medical devices, sold through a direct enterprise sales motion targeting Japanese hospitals, complemented by channel partnerships with PACS providers (Jamac System) and medical equipment distributors (Ryukyu Kowa). Customers include more than 1,000 medical institutions across all 47 Japanese prefectures, plus major pharmaceutical companies (Takeda, Astellas, Daiichi Sankyo, Taiho) for drug discovery image analysis. Distribution is increasingly bundled into OEM platforms of Canon Medical Systems (Abierto), Siemens Healthineers (teamplay), NOBORI, M3, and Alamy Join AI Connect, giving LPIXEL reach into installed bases of imaging hardware and PACS networks. Strategic capital partners include Canon Medical Systems, Fujifilm, Olympus, Cyberdyne, and JAFCO, with cumulative disclosed funding of approximately $43 million across Series A (2016), a strategic round (2018), and follow-on capital in 2020 and 2025.

LPIXEL firmographics

Firmographics
Name
LPIXEL
Legal name
エルピクセル株式会社
Website
https://lpixel.net
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
LPIXEL is a Japan-based medical AI company that develops regulated deep-learning image-analysis software (EIRL suite) for radiology, endoscopy, and surgical guidance, serving hospitals and pharmaceutical research customers across Japan and expanding into ASEAN and MENAT markets.
Ownership category
akta.pro rank

LPIXEL industry classification

Industry
Product category
Medical Imaging AI / Diagnostic Imaging Software
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Software Publishers (5132)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Medical imaging AI
  • Diagnostic support software
  • Radiology workflow
  • Drug discovery AI
  • Medical device software

Where LPIXEL is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

LPIXEL business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. SaaS Subscription: Cloud-based subscription model providing AI analysis services to medical institutions on a recurring basis
  2. Per-Case Pricing: Usage-based pricing where healthcare facilities pay per analysis performed
  3. Medical Device Sales: Sale of certified medical device software products (EIRL series)

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise institutional licensing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

LPIXEL product offering

Product offering

Core offering

LPIXEL develops and sells AI-powered medical image diagnostic support software (EIRL series) covering brain MRI, chest X-ray, chest CT, and colonoscopy analysis for hospitals and clinics, as well as the IMACEL cloud platform for AI-assisted drug discovery research and ImaChek for image integrity checking in scientific publications. Products are deployed as regulated Software as a Medical Device (SaMD) with PMDA approval, EN ISO 13485:2016 certification, and integrations with PACS, medical imaging equipment, and cloud platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • EIRL (エイル): AI medical image diagnostic support technology for clinical use, including brain MRI, chest X-ray, and colonoscopy analysis.
  • IMACEL (イマセル)
  • ImaChek (イマチェック)

Products and services

  • EIRL Brain Aneurysm AI-powered Software as a Medical Device that analyzes brain MRI images to detect cerebral aneurysms, designed for radiology departments in hospitals and imaging centers.
  • EIRL BRAIN AI brain MRI analysis product family for detecting and characterizing brain lesions, used by radiologists in clinical practice.
  • EIRL Chest Nodule AI software that detects lung nodule candidate areas from chest X-ray images for radiologist review.
  • EIRL Chest Screening Multifunctional chest X-ray AI product integrating lung nodule detection and quantitative chest measurements for screening workflows.
  • EIRL Chest CT AI software for detecting lung nodule candidate areas from chest CT images, expanding the EIRL chest product line beyond X-ray.
  • EIRL Colon Polyp AI-assisted colonoscopy analysis software that detects colon polyp candidates in real time and assists in colonoscopy procedures, compatible with Olympus and Fujifilm endoscope systems.
  • EIRL Viewer Medical imaging display and analysis platform for viewing and interpreting EIRL AI analysis results within clinical workflows.
  • EIRL Surgery LC AI-powered landmarking and guidance system for laparoscopic cholecystectomy, supporting minimally invasive surgical procedures.
  • IMACEL AI-based image analysis cloud platform for drug discovery and life science research, supporting study design, seeds findings, and evaluation of diseases through phenotypic screening and cell morphology analysis.
  • IMACEL Platform Cloud-based image analysis AI platform for drug discovery and academic research, providing efficiency, quality, and safety improvements across the drug development pipeline.
  • ImaChek Automated image manipulation and duplication checking system that extracts images from PDF scientific papers and compares them against databases to detect image fraud and honest errors, supporting research integrity.

Quantifiable outcome

  • Over 1,000 medical institutions across Japan using LPIXEL solutions
  • +2 more outcomes

Companies that use LPIXEL

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

LPIXEL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability9 records

Feature5 records

LPIXEL partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major, core, notable and minor.

  • Jameel HealthmajorStrategic or Co-development Partner · 1 January 2022Strategic collaboration to expand AI medical imaging solutions to MENAT (Middle East, North Africa, Turkey) and Global South markets. Joint go-to-market efforts for healthcare AI deployment.
  • Daiichi SankyocoreStrategic or Co-development Partner · 1 January 2021Comprehensive partnership for AI image analysis in pharmaceutical research and drug development. Collaboration focused on applying AI image analysis to support Daiichi Sankyo's drug development pipeline.
  • Olympus CorporationcoreStrategic or Co-development Partner · 1 January 2019Strategic partnership for AI-based landmarking and guidance system for laparoscopic cholecystectomy. Joint development of AI-powered surgical guidance technology for minimally invasive procedures.
  • CYBERDYNEnotableStrategic or Co-development PartnerBusiness alliance for potential synergies in medical technology and AI solutions. Collaborative exploration of healthcare AI applications.
  • NTT DatanotableTechnology or IntegrationTechnology partnership for system integration and deployment of AI medical imaging solutions. Collaboration on healthcare IT infrastructure.
  • FathomXnotableStrategic or Co-development PartnerPartnership for mammography AI development and deployment. Collaboration on breast cancer screening AI solutions.
  • TakedacoreStrategic or Co-development PartnerAI image analysis partnership for pharmaceutical research and clinical trials. Application of AI to support Takeda's drug development activities.
  • Astellas PharmacoreStrategic or Co-development PartnerStrategic partnership for AI-powered image analysis in pharmaceutical research. Collaboration on applying AI to Astellas research programs.
  • Taiho PharmaceuticalnotableStrategic or Co-development PartnerAI image analysis partnership for research applications. Support for Taiho's pharmaceutical research initiatives.
  • VNPT-ITminorStrategic or Co-development PartnerJoint proof-of-concept initiative in Vietnam for AI medical imaging deployment. Market exploration and pilot programs in Southeast Asia.
  • JTECminorStrategic or Co-development PartnerJoint proof-of-concept in Vietnam. Collaborative pilot programs for AI medical imaging solutions.
  • Tokyo University HospitalcoreStrategic or Co-development PartnerAcademic partnership for clinical validation and research collaboration on AI medical imaging technologies. Joint research and product development.
  • National Cancer Center JapancoreStrategic or Co-development PartnerResearch partnership for cancer screening AI development and clinical validation. Collaborative development of cancer detection AI solutions.
  • Jamac SystemnotableChannel Partner/ Reseller/ DistributorDistribution partnership through PACS provider for market access. Integration and resale of LPIXEL AI solutions through medical imaging systems.
  • Ryukyu KowaminorChannel Partner/ Reseller/ DistributorDistribution partnership for medical imaging products in regional Japan markets.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

LPIXEL competitors and assessment

Company assessment

Direct peers

  • AI Medical Service: Tokyo-based medical AI company developing endoscopy/colonoscopy diagnostic support AI. Directly comparable to LPIXEL as a Japanese SaMD-focused medical imaging AI company with PMDA approvals, hospital channel sales, and overlapping colonoscopy product (EIRL Colon Polyp vs. AI Medical Service's endoscopic AI).
  • icometrix: Belgium-based AI company with FDA-cleared and CE-marked brain MRI quantification tools (icoBrain) for multiple sclerosis, dementia, and traumatic brain injury. Closely comparable to LPIXEL's EIRL Brain Aneurysm in modality (brain MRI), regulatory pathway (SaMD), and clinical use case (neuroimaging decision support).
  • HeartFlow: US-based AI SaMD company analyzing coronary CT angiography for non-invasive FFR assessment. Comparable as a regulated imaging-AI SaMD with similar enterprise hospital sales motion, large PMA/FDA-cleared product portfolio, and reliance on CT scanner-installed-base partnerships.
  • Arterys: US-based cloud-native medical imaging AI platform with FDA-cleared products for cardiac MRI, lung CT, and oncology workflows. Comparable to LPIXEL as a multi-modality cloud imaging AI platform selling to radiology departments through enterprise and PACS channels.

Broad incumbents

  • Aidoc: Israel-based medical imaging AI platform with broad multi-modality FDA-cleared products covering CT, X-ray, and MRI triage and workflow across numerous clinical indications. Competes with LPIXEL's EIRL suite in modality breadth and hospital enterprise sales motion, but at much larger scale (Series D+ funding, global footprint).
  • Viz.ai: US-based AI company specializing in clinical workflow AI for stroke and other time-sensitive conditions, with FDA-cleared products integrated into hospital imaging platforms. Comparable to LPIXEL as a regulated medical imaging AI company selling into enterprise health systems via PACS/workflow integrations, though narrower in modality focus.
  • RapidAI: US-based medical imaging AI company with FDA-cleared products for stroke, aneurysm, and PE imaging analysis on CT/MRI. Directly comparable in regulatory pathway (SaMD clearances), modality overlap (brain aneurysm detection), and enterprise radiology channel to LPIXEL's EIRL Brain Aneurysm.

Emerging players

  • CureMetrix: US-based AI company with FDA-cleared mammography AI for breast cancer detection (cmTriage, cmAssist). Adjacent comparable to LPIXEL via the EIRL AI Partner Program's FathomX mammography integration, sharing the same regulated mammography SaMD category and women's imaging customer base.

Market position

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

LPIXEL social profiles

Digital presence

LPIXEL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LPIXEL leadership team

Management profile

Number of profiles

Profiles8 records

LPIXEL subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

LPIXEL funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LPIXEL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LPIXEL

What does LPIXEL do?

LPIXEL develops and sells AI-powered medical image diagnostic support software (EIRL series) covering brain MRI, chest X-ray, chest CT, and colonoscopy analysis for hospitals and clinics, as well as the IMACEL cloud platform for AI-assisted drug discovery research and ImaChek for image integrity checking in scientific publications. Products are deployed as regulated Software as a Medical Device (SaMD) with PMDA approval, EN ISO 13485:2016 certification, and integrations with PACS, medical imaging equipment, and cloud platforms.

Is LPIXEL a public or private company?

LPIXEL is a private company. It is classified as venture growth investor backed and is currently operating.

When was LPIXEL founded?

LPIXEL was founded in 2014. It employs 11 to 50 people.

Where is LPIXEL based?

LPIXEL is headquartered in Tokyo, Japan, in the Asia region.

How does LPIXEL make money?

Three revenue lines are on record. SaaS Subscription is the primary driver. The others are per-Case Pricing and medical Device Sales.

Who are LPIXEL's main competitors?

Direct peers on record are AI Medical Service, icometrix, HeartFlow and Arterys. Broad incumbents are Aidoc, Viz.ai and RapidAI. CureMetrix is listed as an emerging player.

Does LPIXEL have an API?

No public API is recorded for LPIXEL.

What industry is LPIXEL in?

LPIXEL's product category is Medical Imaging AI / Diagnostic Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 33451 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Prtimes胸部X線診断支援AI「EIRL Chest Screening」を大幅アップデートElpixel updated its chest X-ray diagnostic support AI, EIRL Chest Screening. The system is used in over 1,200 facilities across all 47 prefectures, with more than 16 million analyses completed as of February 2026.Prtimes胸部CT画像診断支援AI「EIRL Chest CT」、計測機能の拡充機能等を追加した新モデルを発売Lpixel Inc. launched a new version of its EIRL Chest CT AI, adding expanded quantitative measurement functions and RaySum image output. The features support lung cancer screening guidelines and aim to reduce physician workload. The product is already used in over 1,200 facilities.PrtimesAIによる内視鏡外科情報手術支援システム「EIRL Surgery LC」が薬事承認を取得Oita University and Fukuoka Institute of Technology announced regulatory approval for their AI endoscopic surgery support system 'EIRL Surgery LC' under Japan's Pharmaceuticals and Medical Devices Act. The system analyzes endoscopic images in real time to visualize anatomical landmarks around the gallbladder, aiming to prevent bile duct injuries. It is compatible with Olympus' VISERA ELITEIII and will be evaluated in clinical institutions for insurance coverage.PrtimesThe image diagnostic support AI series "EIRL" has obtained regulatory approval in six Southeast Asian countries.EIRL, a medical image analysis AI by Lpixel, received regulatory approval in six Southeast Asian countries: Vietnam, Philippines, Thailand, Indonesia, Malaysia, and Singapore. The AI supports detection of lung nodules and tuberculosis classification from chest X-rays. Sales will begin once preparations are complete, with trial implementations already underway.openPR.comJapan AI in Healthcare Market to Reach US$14.8 Billion by 2033 at 36.5% CAGR; Kanto Region Leads with 46% Share, Key Players: IBM, FUJITSU, Microsoft, LPixel Inc.The Japan AI in Healthcare Market reached US$1.42 billion in 2024 and is projected to grow to US$14.8 billion by 2033, at a compound annual growth rate of 36.5% during the forecast period 2025–2033. Key developments include product launches by Fujifilm Corporation, partnerships such as LPixel Inc. with Tokyo University Hospital, and M&A activity including Hitachi Ltd.'s acquisition of a domestic AI-health analytics startup. The Kanto region dominates with 46% market share, driven by Tokyo's concentration of hospitals, research institutions, and technology firms, while regulatory challenges around data privacy under Japan's Act on the Protection of Personal Information remain a restraint.NatureHarnessing AI to improve drug discoveryDaiichi Sankyo partnered with LPIXEL to develop an AI system for phenotypic screening, using nuclear morphology to assess drug responsiveness. The system, built from March 2018 to March 2020, can detect morphological changes invisible to the human eye. LPIXEL plans to roll out the technology to other pharma and biotech companies.